Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1328 • ACR Convergence 2024
Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study
Roslin Jose George¹, Noah Frechette¹, Iqra Javed¹, Bradly Kimbrough², Sara Achenbach³, Elena Joerns¹, Vanessa Kronzer¹, John Davis¹, Cynthia Crowson¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Carpal tunnel syndrome (CTS) is a common complication of rheumatoid arthritis (RA). However, the occurrence of CTS before RA and the effect of RA…
Abstract Number: 1344 • ACR Convergence 2024
Forced Vital Capacity Trajectories and Risk of Lung Transplant and ILD-Related Mortality Among Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease
Rathnam Venkat¹, Keigo Hayashi², Pierre-Antoine Juge³, Gregory McDermott², Misti Paudel⁴, Xiaosong Wang⁵, Kathleen Vanni⁵, Emily Kowalski⁶, Grace Qian⁵, Katarina Bade⁶, Alene Saavedra⁶, Kevin Mueller⁶, Sung Hae Chang⁷, Paul Dellaripa⁶, Michael Weinblatt⁸, Nancy Shadick⁵, Tracy J Doyle⁹, Philippe Dieudé¹⁰ and Jeffrey Sparks¹¹, ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women’s Hospital, Brookline, MA, ³Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women’s Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, ⁸Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁹Brigham and Women's Hospital, West Roxbury, MA, ¹⁰Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is heterogeneous with about half of patients having progressive disease. However, the rates of progression and the association…
Abstract Number: 1360 • ACR Convergence 2024
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Urbano Sbarigia¹, Jing Zhao², Jackie Kwong², Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
Abstract Number: 1376 • ACR Convergence 2024
Comparison of the Efficacy of DMARDs in Phase 3 Trials of Different Populations Used in FDA Approvals for Rheumatoid Arthritis Since 2010
Catherine Emanuel¹ and Ajay Aggarwal², ¹Aclaris Therapeutics Inc., St Louis, MO, ²Aclaris Therapeutics, Inc., Wellesley, MA
Background/Purpose: Varying mechanisms of action are required to address the needs of rheumatoid arthritis patients with different levels of severity. Since 2010, all new FDA…
Abstract Number: 1393 • ACR Convergence 2024
Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials
Roy Fleischmann¹, Zoltán Szekanecz², Eduardo Mysler³, Kevin Winthrop⁴, Kunihiro Yamaoka⁵, Kirsten Famulla⁶, Yanna Song⁷, Birgit Kovacs⁷, Sander Strengholt⁸ and Gerd Burmester⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Debrecen, Debrecen, Hungary, ³Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, ⁴School of Medicine, Oregon Health and Science University, Portland, OR, ⁵Kitasato University School of Medicine, Sagamihara, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, ⁷AbbVie, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Patients with RA are at a heightened risk of developing significant adverse events (AEs) such as MACE, VTE, and serious infectious events (SIE). Limited…
Abstract Number: 1661 • ACR Convergence 2024
Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation
Melissa Romoff¹, Daniel Ramirez², Edward Dicarlo³, Susan Goodman⁴, Alexander Rudenska⁵, Laura Donlin¹ and Melanie Smith¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Cartago, Costa Rica, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York 10025, NY, ⁵Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: In the rheumatoid arthritis (RA) joint, resident synovial fibroblasts (FLS) interact with infiltrating leukocytes. We previously identified a population of sublining FLS responsive to…
Abstract Number: 1743 • ACR Convergence 2024
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Jing Zhao¹, Urbano Sbarigia², Jackie Kwong¹, Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
Abstract Number: 1871 • ACR Convergence 2024
A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population
Tada Vargas¹, Lauren Vanderlinden², Patrick Carry³, Kristen Demoruelle⁴, Marie Feser¹, Katerina Kechris⁵, Jane Buckner⁶, William Robinson⁷, Gary Firestein⁸, Michael Holers¹, Kevin Deane⁹ and Jill Norris¹⁰, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Colorado School of Public Health, Monument, CO, ³Department of Orthopedics, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO, ⁵Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Benaroya Research Institute, Seattle, WA, ⁷Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA, ⁸University of California, San Diego, San Diego, CA, ⁹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹⁰Colorado School of Public Health, Denver, CO
Background/Purpose: Serum autoantibodies, such as ACPA and RF, are commonly detectable prior to the development of seropositive clinical RA; however, not all individuals with these…
Abstract Number: 1954 • ACR Convergence 2024
Examination of Rehabilitation Referrals from Rheumatology Practices for Adults with Rheumatoid Arthritis in the RISE Registry: A Feasibility and Descriptive Study
Louise Thoma¹, Jing Li² and Gabriela Schmajuk³, ¹University of North Carolina, Chapel Hill, NC, ²University of California, San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Adults with rheumatoid arthritis (RA) commonly report functional limitations, pain, and fatigue that contribute to diminished quality of life and limit participation in valued…
Abstract Number: 2168 • ACR Convergence 2024
Two Year Data on Quality of Life, Pain and Mobility Scores After Rituximab Treatment in the Preclinical Phase of Rheumatoid Arthritis
Giulia Frazzei¹, Sophie Cramer¹, Robert Landewé², Karen Maijer³, Danielle Gerlag⁴, Paul Tak, MD PhD⁵, Niek De Vries⁶, Lisa van Baarsen⁶, Ronald Van Vollenhoven⁷ and Sander Tas⁸, ¹Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, ²Amsterdam University Medical Center, Meerssen, Netherlands, ³Tergooi Hospital, Hilversum, Amsterdam, Netherlands, ⁴UCB, Cambridge, United Kingdom, ⁵Candel Therapeutics, Cambridge, United Kingdom, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Over the past 10 years, several trials have investigated prevention of rheumatoid arthritis (RA) by disease modifying antirheumatic drug (DMARD) therapies. Early treatment of…
Abstract Number: 2225 • ACR Convergence 2024
Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
Maria Rodriguez-Laguna¹, Leticia Leon², Dalifer Freites Nuñez³, Cristina Hormigos-martin⁴, jose otazu Moudelle⁴, Alfredo Madrid García⁵, Benjamin fernandez-Gutierrez² and lydia Abasolo Alcazar⁶, ¹Resident in Rheumatology, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁴Hospital Clínico San Carlos, madrid, Spain, ⁵Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IDISCC), Madrid, Madrid, Spain, ⁶IdISSC. HCSC, Madrid, Spain
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) who remains symptomatic after failing to multiple therapies are deemed to have "difficult-to-treat" (D2T RA). Fatigue…
Abstract Number: 2241 • ACR Convergence 2024
Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Bindee Kuriya³, Sibel Aydin⁴, Ed Keystone⁵, Janet Pope⁶ and Claire Bombardier⁷, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto - Toronto, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶University of Western Ontario, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of hospitalizations and mortality due to RA itself, associated comorbidities, and treatment-related complications. The purpose…
Abstract Number: 2261 • ACR Convergence 2024
Risk of Cervical Intraepithelial Neoplasia During Janus Kinase (JAK) Inhibitor Treatment in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Mi-Ra Cho¹, Young-Eun Kim², Yeo-Jin Lee³, Soo Min Ahn², Seokchan Hong¹, Ji Seon Oh¹, Chang-Keun Lee¹, Bin Yoo¹ and Yong-Gil Kim¹, ¹Asan Medical Center, Seoul, Republic of Korea, ²Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ³Asan medical center, Seoul, South Korea
Background/Purpose: Janus kinase (JAK) inhibitors are increasingly used in the treatment of Rheumatoid arthritis (RA); however, concerns have been raised about their potential to elevate…
Abstract Number: 2279 • ACR Convergence 2024
Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care
Isabel Castrejon¹, Lucia Otero-Varela², José María Álvaro-Gracia³, Jerusalem Calvo Gutierrez⁴, Cristina Campos-Fernández⁵, Alicia García Dorta⁶, Ana Perez⁷, DOLORES RUIZ MONTESINO⁸ and Fernando Sánchez-Alonso⁹, and on behalf of BIOBADASER, ¹Hospital General Universitario Gregorio Marañon, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Gregorio Marañón, Madrid, Spain, ⁴HU Reina Sofia, Cordoba, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Rheumatologist, La Laguna, Spain, ⁷Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁸Hospital Virgen Macarena, Sevilla, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) have a rapid effect on symptoms, but chronic exposure is associated to important adverse events. Although both EULAR and ACR guidelines (1,2),…
Abstract Number: 2542 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis
Anders Nguyen¹, Miriam Bollmann¹, Agnieszka Lastowska², Anna-Karin Hultgård Ekwall¹, Dietmar Zaiss³, Gary Firestein⁴ and Mattias Svensson⁵, ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Goteborg, Sweden, ³University Hospital Regensburg, Regensburg, Germany, ⁴University of California, San Diego, San Diego, CA, ⁵University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Activation of fibroblast-like synoviocytes (FLS) by immune cells drives inflammation and joint damage in rheumatoid arthritis (RA). Hence, understanding factors that induce destructive behaviors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].